Announced Mon, 5 Oct, 2026 · 16:19 IST
Board meeting on 14 Oct 2026 to consider Q2 FY27 results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-7.2%1-day move
₹27.49
prior close
₹28.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.6-0.6-3.6-7.2-11.9————————
Up moveDown movePending
AI summary
Standard intimation under SEBI LODR Regulation 29. The Board of Directors of Bacil Pharma will meet on 14 October 2026 to consider and approve the unaudited financial results for the quarter and half year ended 30 September 2026, along with any other business permitted by the Chairperson. Signed by Chaitali Kalpataru Shah, Managing Director.
Likely market impact
Routine filing. Investors should watch for the results announcement on or after 14 October 2026 to gauge quarterly performance.